Cover Image
市場調查報告書

停經後骨質疏鬆症:開發中產品分析

Post Menopausal Osteoporosis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213136
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
Back to Top
停經後骨質疏鬆症:開發中產品分析 Post Menopausal Osteoporosis - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 86 Pages
簡介

所謂停經後骨質疏鬆症,是骨質疏鬆症最常見的形態,很多停經後的女性罹患。症狀有背痛和身高降低,駝背姿勢等脊椎變形。風險係數有年齡、性別、家族病史、骨結構、體重等,治療方法有荷爾蒙補充療法(HRT),維他命D3衍生物的給藥等。

本報告涵括全球停經後骨質疏鬆症治療藥的開發平台,提供目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等資訊,為您概述為以下內容。

簡介

  • 調查範圍

停經後骨質疏鬆症概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的治療藥
  • 企業開發中的產品

停經後骨質疏鬆症:治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

停經後骨質疏鬆症的治療藥開發企業

  • Amgen Inc
  • Enteris BioPharma Inc
  • Intas Pharmaceuticals Ltd
  • Ipsen SA
  • Ligand Pharmaceuticals Inc
  • Lupin Ltd
  • NIBEC
  • Oncobiologics Inc
  • Paras Biopharmaceuticals Finland Oy

藥物簡介

停經後骨質疏鬆症:暫停中的計劃

停經後骨質疏鬆症:開發中止的產品

停經後骨質疏鬆症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9820IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H2 2017, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I and Preclinical stages are 4, 2, 1 and 7 respectively.

Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Post Menopausal Osteoporosis - Overview
    • Post Menopausal Osteoporosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Post Menopausal Osteoporosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development
    • Amgen Inc
    • Enteris BioPharma Inc
    • GL Pharm Tech Corp
    • Intas Pharmaceuticals Ltd
    • Ipsen SA
    • Lupin Ltd
    • Luye Pharma Group Ltd
    • NIBEC
    • Oncobiologics Inc
    • Paras Biopharmaceuticals Finland Oy
    • Sermonix Pharmaceuticals LLC
  • Post Menopausal Osteoporosis - Drug Profiles
    • (cholecalciferol + risedronate sodium) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • abaloparatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • calcitonin DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • denosumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lasofoxifene tartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • romosozumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide for Obesity and Post Menopausal Osteoporosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teriparatide biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Post Menopausal Osteoporosis - Dormant Projects
  • Post Menopausal Osteoporosis - Discontinued Products
  • Post Menopausal Osteoporosis - Product Development Milestones
    • Featured News & Press Releases
      • Oct 13, 2017: Radius Health to Present First Health Economics Data on TYMLOS (abaloparatide) Injection at the Academy of Managed Care Pharmacy Nexus 2017
      • Sep 11, 2017: EVENITY (romosozumab) ARCH Study Results Published In The New England Journal Of Medicine
      • Sep 10, 2017: Radius Health Presents Positive Data for TYMLOS (abaloparatide) Injection from the ACTIVExtend Trial at ASBMR 2017 Annual Meeting
      • Sep 08, 2017: Amgen Highlights Prolia (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting
      • Sep 08, 2017: UCB highlights latest EVENITY research at the American Society for Bone and Mineral Research Annual Meeting
      • Sep 01, 2017: Radius Health to Present Eight Abstracts at the American Society of Bone and Mineral Research (ASBMR) 2017 Annual Meeting Including Results of the ACTIVE and ACTIVExtend Trials for TYMLOS (abaloparatide) Injection
      • Jul 21, 2017: Radius Health Announces that the CHMP Has Issued a Second Day-180 List of Outstanding Issues in its Regulatory Review of Eladynos (Abaloparatide-SC), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
      • Jul 16, 2017: Amgen And UCB Provide Update On Regulatory Status Of EVENITY (romosozumab) In The US
      • Jun 14, 2017: New class drug significantly reduces spine fracture risk in postmenopausal women with osteoporosis
      • May 24, 2017: Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS in Postmenopausal Women with Osteoporosis
      • May 21, 2017: Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY (Romosozumab) In Postmenopausal Women With Osteoporosis
      • Apr 28, 2017: FDA Approves Radius Healths TYMLOS (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
      • Apr 07, 2017: Osteoporosis drug found safe in long-term trial
      • Apr 03, 2017: New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies
      • Apr 01, 2017: Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY (romosozumab)
      • Appendix
  • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Post Menopausal Osteoporosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Post Menopausal Osteoporosis - Pipeline by Amgen Inc, H2 2017
  • Post Menopausal Osteoporosis - Pipeline by Enteris BioPharma Inc, H2 2017
  • Post Menopausal Osteoporosis - Pipeline by GL Pharm Tech Corp, H2 2017
  • Post Menopausal Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H2 2017
  • Post Menopausal Osteoporosis - Pipeline by Ipsen SA, H2 2017
  • Post Menopausal Osteoporosis - Pipeline by Lupin Ltd, H2 2017
  • Post Menopausal Osteoporosis - Pipeline by Luye Pharma Group Ltd, H2 2017
  • Post Menopausal Osteoporosis - Pipeline by NIBEC, H2 2017
  • Post Menopausal Osteoporosis - Pipeline by Oncobiologics Inc, H2 2017
  • Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2017
  • Post Menopausal Osteoporosis - Pipeline by Sermonix Pharmaceuticals LLC, H2 2017
  • Post Menopausal Osteoporosis - Dormant Projects, H2 2017
  • Post Menopausal Osteoporosis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Post Menopausal Osteoporosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top